TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07808151: Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

Sponsor: Solstice Oncology, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT07808151 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07808151 Rescue Dossier →